DS
VYGR icon

David Shaw’s Voyager Therapeutics VYGR Stock Holding History

David Shaw’s Portfolio VYGR Stock Details VYGR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$504K Buy
143,992
+45,276
+46% +$172K ﹤0.01% 4175
2026
Q1 		$381K Buy
+98,716
New +$389K ﹤0.01% 3979
2024
Q4 		– Sell
-118,828
Closed -$695K – 4931
2024
Q3 		$695K Sell
118,828
-86,773
-42% -$631K ﹤0.01% 3510
2024
Q2 		$1.63M Sell
205,601
-28,388
-12% -$238K ﹤0.01% 2841
2024
Q1 		$2.18M Sell
233,989
-172,055
-42% -$1.45M ﹤0.01% 2571
2023
Q4 		$3.43M Sell
406,044
-220,079
-35% -$1.6M ﹤0.01% 2237
2023
Q3 		$4.85M Sell
626,123
-321,850
-34% -$2.94M 0.01% 1831
2023
Q2 		$10.9M Buy
947,973
+319,501
+51% +$3.31M 0.01% 1274
2023
Q1 		$4.85M Sell
628,472
-60,228
-9% -$479K 0.01% 1956
2022
Q4 		$4.2M Sell
688,700
-16,076
-2% -$91.3K ﹤0.01% 2256
2022
Q3 		$4.17M Sell
704,776
-22,366
-3% -$143K 0.01% 2293
2022
Q2 		$4.3M Buy
727,142
+90,921
+14% +$614K 0.01% 2317
2022
Q1 		$4.85M Buy
636,221
+342,198
+116% +$1.53M ﹤0.01% 2348
2021
Q4 		$797K Buy
+294,023
New +$1M ﹤0.01% 4102
2020
Q3 		– Sell
-19,927
Closed -$251K – 4195
2020
Q2 		$251K Sell
19,927
-16,776
-46% -$195K ﹤0.01% 3697
2020
Q1 		$336K Sell
36,703
-153,303
-81% -$1.76M ﹤0.01% 3412
2019
Q4 		$2.65M Buy
190,006
+14,620
+8% +$213K ﹤0.01% 2248
2019
Q3 		$3.02M Sell
175,386
-88,076
-33% -$1.85M ﹤0.01% 2052
2019
Q2 		$7.17M Buy
263,462
+22,857
+9% +$523K 0.01% 1331
2019
Q1 		$4.61M Buy
240,605
+201,274
+512% +$2.62M 0.01% 1594
2018
Q4 		$370K Buy
+39,331
New +$505K ﹤0.01% 3256
2017
Q4 		– Sell
-10,621
Closed -$219K – 3759
2017
Q3 		$219K Buy
+10,621
New +$120K ﹤0.01% 3278

Other funds holding VYGR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

David Shaw's VYGR Position: Q2 2026 in Review

David Shaw increased its Voyager Therapeutics (VYGR) stake by 46% in Q2 2026, buying an estimated $172K and bringing the position to 143,992 shares worth $504K. The position accounts for ﹤0.01% of the portfolio, ranked #4175.

David Shaw first reported a position in VYGR in Q3 2017 and has held it in 22 quarters since. The position peaked at $10.9M in Q2 2023. 135 funds tracked by Wall St. Rank hold VYGR as of Q2 2026.

  • David Shaw held 143,992 shares of Voyager Therapeutics worth $504K as of Q2 2026.
  • David Shaw bought 45,276 Voyager Therapeutics shares in Q2 2026, an estimated $172K.
  • Voyager Therapeutics made up ﹤0.01% of David Shaw's portfolio in Q2 2026, its #4175 holding.
  • David Shaw first reported a position in Voyager Therapeutics in Q3 2017 and has held it in 22 quarters since.
  • David Shaw's Voyager Therapeutics position peaked at $10.9M in Q2 2023.
  • 135 funds tracked by Wall St. Rank held Voyager Therapeutics as of Q2 2026.

Based on D.E. Shaw & Co's 13F filing for Q2 2026, filed 14 Aug 2026.